International AMR Action! 21 Sep Wellcome Trust-UNGA event / 12-13 Oct Call to Action (Berlin)

Dear All: 

The international conversation continues apace following the recent DRIVE-AB meeting on antibiotic incentives. There are two further important meetings coming up that you may wish to know about.

First, Wellcome Trust is co-hosting a side-event with the UN Foundation during the UN General Assembly on 21 Sep (yes, this week!). The side event is from 8a-10a in New York City. Here is the registration link should you be in NYC on Thursday and able to attend. Panel discussions will focus on the challenges of developing multi-sectoral national action plans as well as covering progress on support mechanisms for antibiotic discovery. The keynote speakers look wonderful, including opening comments from the WHO’s DG:

  • Session title: One Year On: Progress, Challenges, Opportunities, and New Ways of Working to Tackle Antimicrobial Resistance (AMR)
  • Keynote: Dr. Tedros Adhanom Ghebreyesus; Director-General, World Health Organization; Co-Chair, UN Interagency Coordination Group on AMR
  • Keynote: Professor Dame Sally Davies; Chief Medical Officer, United Kingdom; Co-Convener, UN Interagency Coordination Group
  • Keynote: Ms. Maria Helena Semedo; Deputy Director-General, Food and Agriculture Organization of the United Nations
  • Closing: Honorable Dr. Aaron Motsoaledi; Minister of Health, South Africa

Second, Wellcome Trust is also organizing an AMR Call to Action Conference 12-13 October in Berlin. The event is “… an opportunity for national governments and multilateral institutions to come together with the civil society, private and philanthropic sectors to focus on the most critical gaps in tackling the development and spread of drug-resistant infections, and to commit to concerted and tangible actions.” If you think you might be interested in attending (it is invitation-only but I am told there is still some scope to add attendees), please contact Wellcome Trust by email at amrcalltoaction@wellcome.ac.uk.

It is fabulous to see these conversations at the political level … I know that we don’t yet have all the tools we need to ensure a vibrant antibiotic pipeline, but these conversations are the necessary prelude!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/

Upcoming meetings of interest to the AMR community:

Share

Conflict-Borne XDR Superbugs: It’s Time for the PASTEUR Act!

Dear All: The recent publication of an exceptionally good plain-language summary of the AMR problem in Rolling Stone (yes, you read that correctly!) prompts today’s 3-part journey into the way(s) that war contributes to the threat of resistant superbugs. We’ve summarized the story in outline form — please explore the references for further details. And

ENABLE-2 funding now includes Hit Identification & Validation

23 July 2024 addenda x 2:  Mark Blaskovich let me know that the CO-ADD project is still offering a free in vitro screening service. See https://www.co-add.org/ to submit compounds for free testing vs 5 bacteria and 2 fungi; see https://db.co-add.org/ for structures and screening data on >100K compounds. The GHIT Fund has announced its 21st Request for Proposals for its Hit-to-Lead Platform to

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

Scroll to Top